<DOC>
	<DOCNO>NCT01998802</DOCNO>
	<brief_summary>This phase III double-masked , randomize , control study evaluate efficacy EBI-005 compare vehicle give topical ophthalmic solution eye subject moderate severe DED three time daily 12 week . Approximately 730 subject approximately 50 center United States screen , enrol study .</brief_summary>
	<brief_title>Phase 3 Study EBI-005 Dry Eye Disease</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<criteria>Give write informed consent authorization require local law ( e.g. , Protected Health Information waiver ) prior perform study procedure ; Are â‰¥ 18 year age ; Are willing able follow instruction present require study visit duration study ; Have history dry eye disease ( DED ) eye support previous clinical diagnosis Have normal lid anatomy . If female child bear potential , must pregnant lactate sexually active ( abstinent ) within 14 day prior Visit 1 Have sign infection ( i.e. , fever current treatment antibiotic ) Have expose investigational drug/device within precede 30 day Be employee site directly involved management , administration , support study , immediate family member Be unwilling unable comply study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>